HopeStage
Back to all studies
CompletedNCT04466345

Semaglutide for Thinking Difficulties in Major Depression

About this titleRead the official source — NCT04466345
Placebo comparisonAges 18–60Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 6, 2021
Recruitment status
Completed
Enrollment listed in the registry
72
Sponsor
University Health Network, Toronto
Sponsor type
University
Study type
Biological
Intervention type
Biological
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
From 18 Years to 60 Years
Official registry ID
NCT04466345
Official title
Show the full official title

Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Health Network, Toronto, a university.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies